CGM After Discharge From Hospital

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT07510386
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Libre 3 Plus continuous glucose monitoring (CGM) system — DEVICE
    Use of unmasked CGM after discharge
  • Blinded Continuous Glucose Monitoring — DEVICE
    Masked CGM
  • Finger stick — BEHAVIORAL
    Self-monitoring blood glucose

Study Details

This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.

Key Dates

Start date
Apr 30, 2026
Status verified
Mar 2026
Primary completion
Oct 31, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
64 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Libre 3 Plus continuous glucose monitoring (CGM) system
    use of unmasked continuous glucose monitoring
  • Active Comparator: Blinded CGM and fingerstick monitoring
    Self-monitoring blood glucose (SMBG)+masked CGM

Primary Outcome Measure

time in range 70-180 mg/dl [ Time Frame: Day 20-30 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10035
Grenye O'Malley, MD
grenye.o'[email protected]
212-241-7173
Sophie Baum
[email protected]
Grenye O'Malley (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies